Stock of the Day

Madrigal Pharmaceuticals (MDGL)

$313.40

-$17.54 (-5.3%)

Market Cap: $6.96B

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

The company is headquartered in West Conshohocken, Pennsylvania.

Recent News

• Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH (globenewswire.com)
• Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $931,039.37 in Stock (insidertrades.com)
• Madrigal Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark (msn.com)
• Madrigal stock jumps as patent protection for MASH treatment extended (in.investing.com)
• Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy (msn.com)
• Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffraâ„¢ (Resmetirom) (globenewswire.com)